IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor: Immunovant Sciences GmbH
Listed as NCT07032662, this observational or N/A phase trial focuses on Chronic Inflammatory Demyelinating Polyneuropathy and remains actively recruiting participants. Sponsored by Immunovant Sciences GmbH, it has been updated 5 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IMVT-1402 in adult participants with active CIDP.
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IMVT-1402 in adult participants with active CIDP.
Status Flow
Change History
5 versions recorded-
Apr 23, 2026 — Present [daily]
Recruiting
Phase: PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE2
First recorded
Mar 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
Contact Information
- Immunovant Sciences GmbH
For direct contact, visit the study record on ClinicalTrials.gov .